Cancer Centers in the News

The following links highlight some of the most up-to-date news from the 27 NCCN Member Institutions. The media coverage below includes major national news outlets, industry magazines, medical journals, and press releases.

The news is listed in reverse chronological order for ease of use.

08/11/2017
New NCCN Patient Resources for Rectal Cancer Now Available

Together with the NCCN Guidelines for Patients®: Colon Cancer, these free resources aid in decision-making for patients with colon and rectal cancers.

 

[FORT WASHINGTON, PA — August 11, 2017] It is estimated that more than 39,900 new cases of Rectal Cancer and more than 95,000 new cases of Colon Cancer will be diagnosed this year in the United States. In fact, Colorectal Cancer—Colon and Rectal Cancers together—is the third most commonly diagnosed cancer in both men and women.1 While Colon and Rectal Cancers share like disease symptoms and characteristics, it is imperative that patients with Rectal Cancer have access to treatment information tailored specifically to their diagnosis.

To empower patients with Rectal Cancer to make informed choices about their cancer care, the National Comprehensive Cancer Network® (NCCN®), through funding from NCCN Foundation®, have published the new NCCN Guidelines for Patients® and NCCN Quick Guide™ sheet for Rectal Cancer. These resources, as well as the NCCN patient resources for Colon Cancer published earlier this year, arm patients with the same evidence-based treatment information that their doctors use to aid in the shared-decision-making process with their care teams.

To ensure the resources get into patients’ hands, Fight Colorectal Cancer has sponsored both the NCCN Guidelines for Patients®: Colon and Rectal and directs patients to them through their medically-reviewed patient education materials on their website, such as Your Guide in the Fight and other blogs and web pages.

“NCCN Foundation is incredibly grateful to Fight Colorectal Cancer for their generous support of both the NCCN Guidelines for Patients for Colon and Rectal Cancers,” said Marcie R. Reeder, MPH, Executive Director, NCCN Foundation. “With more than 100,000 new cases of Colorectal Cancer diagnosed in the United States each year, we are pleased to now be able to empower the total patient population with the most up-to-date clinical options available to them at every stage of their cancer journey.”

NCCN Guidelines for Patients are easy-to-understand adaptations based on the same clinical practice guidelines used by health care professionals around the world to determine the best way to treat a person with cancer. Each resource features unbiased expert guidance from the nation’s leading cancer centers designed to help people living with cancer understand and discuss their treatment options with their providers.

"We are proud to support the evidence-based NCCN Guidelines for Patients for both Colon and Rectal cancers this year,” said Anjee Davis, President of Fight Colorectal Cancer. “We see these tools as invaluable resources to patients. The publications give our community the latest information on the standards of care in a patient-friendly way while providing the most updated information on clinical practice guidelines for health care providers."

“It is so important for patients and their families to have access to reliable, up-to-date and understandable information about their cancer to assist in composing questions and making decisions about their care when seeking guidance from their clinicians. The NCCN Guidelines for Patients and NCCN Quick Guide™ sheet for Rectal Cancer are such tools that we hope will be invaluable to those with rectal cancer and their friends and family as they manage the complexities of this disease,” said Al B. Benson, III, MD, Associate Director for Cooperative Groups, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and Chair of the NCCN Guidelines Panels for Colon, Rectal, and Anal Cancers. “Patient advocacy groups are important partners for both patients and clinicians and we are so grateful that Fight Colorectal Cancer has partnered with us at NCCN to create this new information and decision tool for patients everywhere.”

NCCN Guidelines for Patients and NCCN Quick Guide™ sheets—one-page summaries of key points in the patient guidelines—are written in plain language and include patient-friendly tools, such as questions to ask your doctor, a glossary of terms, and medical illustrations of anatomy, tests, and treatment. NCCN Guidelines for Patients and NCCN Quick Guide™ sheets DO NOT replace the expertise and clinical judgment of the clinician.

NCCN currently offers patient education materials for the following: Brain, Breast, Colon, Distress, Esophageal, Kidney, Non-Small Cell Lung, Ovarian, Pancreatic, Prostate, Rectal, Stomach, and Thyroid Cancers; Acute Lymphoblastic Leukemia; Adolescents and Young Adults with Cancer; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Hodgkin Lymphoma; Lung Cancer Screening; Malignant Pleural Mesothelioma; Melanoma, Multiple Myeloma; Myelodysplastic Syndromes; Nausea and Vomiting; Non-Hodgkin’s Lymphomas; Soft Tissue Sarcoma; and Waldenström’s Macroglobulinemia.

The NCCN Guidelines for Patients and NCCN Quick Guide™ sheet for Rectal Cancer are available to download free of charge from NCCN.org/patients and the NCCN Patient Guides for Cancer mobile app.

###

About NCCN Foundation®
NCCN Foundation® was founded by the National Comprehensive Cancer Network® (NCCN®) to empower people with cancer and advance oncology innovation. NCCN Foundation supports people with cancer and their caregivers at every step of their treatment journey by delivering unbiased expert guidance from the world’s leading cancer experts through the library of NCCN Guidelines for Patients® and other patient education resources. NCCN Foundation is also committed to advancing cancer treatment by funding the nation’s promising young investigators at the forefront of cancer research, initiating momentum in their careers and furthering the betterment of patients through their groundbreaking innovations. For more information about NCCN Foundation, visit NCCNFoundation.org.

About Fight Colorectal Cancer

Fight CRC is a national nonprofit advocacy organization fighting for a cure. It was founded in 2005 by Nancy Roach, a patient advocate who witnessed the need for colorectal cancer advocacy after her mother-in-law’s diagnosis. The organization plays an important role in rallying colorectal cancer advocates to action. Fight CRC is known for activism and patient empowerment throughout patient, academic, political, scientific, medical and nonprofit communities. With a mission focused on advocacy, research, patient education and awareness, the organization serves advocates in every state of the U.S. and many others around the world. Fight CRC is a 4-star charity by Charity Navigator and 93 cents of every dollar donated goes directly to colorectal cancer programs. To learn more, visit FightCRC.org.

About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.

The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.

Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients. Media, visit NCCN.org/news.


1"Cancer Facts & Figures 2017." American Cancer Society, n.d. Web. 27 July 2017.

>View Article<



08/07/2017
NCCN Foundation Announces Fifth 2017 Young Investigator Award

NCCN Foundation Young Investigator Awards provide funding over a two-year period for research initiatives focused on assessing and improving outcomes in cancer care.

Liqin Zhu, PhD

[FORT WASHINGTON, PA – August 7, 2017] The NCCN Foundation® has granted its fifth Young Investigator Award for the 2017 cycle to Liqin Zhu, PhD, St. Jude Children’s Research Hospital/University of Tennessee Health Science Center, for the study titled, “Patient-Derived Tumor Spheroids for High-Risk Hepatoblastoma Drug Discovery.” Dr. Zhu joins four additional awardees named earlier this year, representing the seventh series of NCCN Foundation Young Investigator Awards—a program initiated in 2011. The grants provide researchers at National Comprehensive Cancer Network® (NCCN®) Member Institutions with funding over a two-year period to each awardee.

“NCCN Foundation is happy to provide funding to Dr. Zhu for study of this rare childhood liver cancer. Identification of biological characteristics of high-risk hepatoblastoma indeed has the potential to aid in discovery of new treatment interventions for this understudied disease,” said Marcie R. Reeder, MPH, Executive Director, NCCN Foundation. “We congratulate Dr. Zhu on her nomination and award and look forward to her contributions to the Young Investigator Award program.”

Following is the full list of 2017 awardees:

  • Kemi Doll, MD, MSCR, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, “Racial Disparities in Endometrial Cancer”
  • Saad Kenderian, MB, CHB, Mayo Clinic Cancer Center, “Chimeric Antigen Receptor T-Cell Therapy in Chronic Lymphocytic Leukemia: Mechanisms of Resistance and Strategies to Enhance Efficacy”
  • Florian Muller, PhD, The University of Texas MD Anderson Cancer Center, “ENO1-Deletion as a Target for Personalized Oncology: Collateral Lethality to the Clinic”
  • Elizabeth Stewart, MD, St. Jude Children’s Research Hospital/University of Tennessee Health Science Center, “Preclinical Match”
  • Liqin Zhu, PhD, St. Jude Children’s Research Hospital/University of Tennessee Health Science Center, “Patient-Derived Tumor Spheroids for High-Risk Hepatoblastoma Drug Discovery”

The awardees responded to a Request for Proposals issued by the NCCN Foundation to the NCCN Member Institutions and were nominated by their institutions. All submissions were reviewed by a multidisciplinary panel of oncology experts; the awardees were selected based on several key components, including scientific merit and study design.  The studies will be managed and overseen by the NCCN Oncology Research Program (ORP).

The 2017 awardees will have the opportunity to present their findings during a future NCCN Annual Conference General Poster Session and their abstracts will be featured in JNCCN – Journal of the National Comprehensive Cancer Network.

Since its inception in 2011, NCCN Foundation has provided funding to 36 U.S. researchers through the Young Investigator Awards. On March 23 and 24, 2017, NCCN featured abstracts from the fifth series of Young Investigator Awards recipients during the NCCN 22nd Annual Conference General Poster Session in Orlando, Florida.

The 2017 NCCN Foundation Young Investigator Awards were made possible through support from AbbVie Inc., Amgen Inc., Genentech, Merck & Co. Inc., Novartis Pharmaceuticals Corporation, Takeda Oncology, and Pfizer Inc.

For more information about the NCCN Young Investigator Awards, visit NCCNFoundation.org.

###

About NCCN Foundation
NCCN Foundation® was founded by the National Comprehensive Cancer Network®(NCCN®) to empower people with cancer and advance oncology innovation. NCCN Foundation supports people with cancer and their caregivers at every step of their treatment journey by delivering unbiased expert guidance from the world’s leading cancer experts through the library of NCCN Guidelines for Patients® and other patient education resources. NCCN Foundation is also committed to advancing cancer treatment by funding the nation’s promising young investigators at the forefront of cancer research, initiating momentum in their careers and furthering the betterment of patients through their groundbreaking innovations. For more information about NCCN Foundation, visit http://www.nccnfoundation.org.

About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.

The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.

Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients. Media, visit NCCN.org/news.

>View Article<



08/07/2017
NCCN “Just Bag It!” Campaign Reaches 100 Adopters Nationwide

100 cancer centers throughout the country have pledged to adopt a life-saving administration policy for vincristine

[FORT WASHINGTON, PA — August 7, 2017] During the launch of the campaign in November 2016, the National Comprehensive Cancer Network® (NCCN®) called on cancer centers and practices that deliver chemotherapy to commit to Just Bag It: The NCCN Campaign for Safe Vincristine Handling. Today, NCCN announces that 100 adopters have confirmed their participation in the effort. The full list is available at NCCN.org/justbagit.

As part of its mission to improve the quality, effectiveness, and efficiency of cancer care so that patients can live better lives, NCCN launched the Just Bag It! campaign to encourage health care providers across the United States and the world to adopt a policy to always dilute and administer vincristine in a mini IV-drip bag to prevent a deadly medical error.

“NCCN commends the efforts of the 100 cancer centers, including the 27 NCCN Member Institutions, who have demonstrated their commitment to patient safety, and we thank them for pushing our message forward,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “NCCN hopes the number of pledges will continue to climb as centers become more aware of this small change that indeed saves patients’ lives.”

Prior to the launch in November, all 27 NCCN Member Institutions had adopted policies in line with the Guidelines, which are also recommended by the Institute for Safe Medication Practices, the Joint Commission, the World Health Organizations and the Oncology Nursing Society. Since the press conference that gained local and national attention, NCCN has continued its campaign through e-mail and social media outreach, as well as live meetings, including the NCCN Patient Advocacy Summit, the NCCN 22nd Annual Conference, and the Oncology Nursing Society Annual Congress.

Vincristine is a chemotherapy agent, widely used in patients with Leukemia or Lymphoma, which should be administered intravenously—directly into the patient’s vein. When it enters the blood, it is highly effective at blocking the growth of cancer by preventing cells from separating. However, vincristine is a neurotoxin that causes peripheral neuropathy when given intravenously and profound neurotoxicity if given into the spinal fluid, which flows around the spinal cord and brain.

Many patients who receive vincristine have a treatment regimen that includes other chemotherapy drugs that are administered intrathecally, or injected into the spinal fluid with a syringe.  If vincristine is administered mistakenly into the spinal fluid, it is uniformly fatal, causing ascending paralysis and eventual death.

In 2005, NCCN Chief Executive Officer Robert W. Carlson, MD, a medical oncologist, witnessed such a tragedy with a 21-year-old patient with Non-Hodgkin’s Lymphoma named Christopher Wibeto. Wibeto was transferred to Dr. Carlson’s care after receiving incorrectly administered vincristine at another hospital. Dr. Carlson watched the young man go from having a treatable condition to deteriorating and dying over the course of four days. Motivated by this tragic experience, Dr. Carlson spearheaded a national effort to address this deadly error when he arrived at NCCN, enlisting the help of its Best Practices Committee, which is dedicated to improving cancer treatment protocols.

“The Just Bag It campaign is the latest of NCCN’s long-standing efforts to improve the safe use of drugs in cancer care,” said F. Marc Stewart, MD, Medical Director of the Seattle Cancer Care Alliance, Member of the Fred Hutchinson Cancer Research Center, Professor of Medicine at University of Washington, and Co-Chair of the NCCN Best Practices Committee. “For more than 15 years, the Best Practices Committee has worked to ensure the highest standards of safety for patients, and we applaud the 100 adopters of this policy at their treatment centers.”

To ensure that vincristine is always administered properly, NCCN has issued guidelines and updated NCCN Chemotherapy Order Templates (NCCN Templates®) advising health care providers to always dilute and administer vincristine in a mini IV-drip bag and never use a syringe to administer the medication. This precaution renders it impossible to accidentally administer the medication into the spinal fluid and greatly decreases the chances of improper dosage.

MiKaela Olsen, MS, APRN-CNS, AOCNS, an oncology nurse at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, one of the NCCN Member Institutions, recently spearheaded a center-wide effort to administer vincristine via mini IV-drip bags, the results of which she presented at the Oncology Nursing Society Annual Congress in May.

“At Johns Hopkins Hospital, our pediatric colleagues made this successful practice change first.  After thoughtful design of the step-by-step procedure, policy revisions, and collaboration between nursing and pharmacy, the change was implemented in adult oncology,” said Ms. Olsen. “Our staff feel confident that this new procedure is safe and that it is absolutely the right thing to do to prevent patient harm. Once we made the change, we did not look back. Eliminating the risk of harm was our number one priority.”

With 125 known cases of accidental death in the United States and abroad since the inception of vincristine use in the 1960s, this error is relatively rare. Still, it is unique in its level of mortality. Improvements in practice over the years, including manufacturer- and pharmacist-issued warning labels, have reduced the number of deaths, but the error continues to occur.

“Every medical center, hospital, and oncology practice that makes the commitment to ‘Just Bag It’ takes an important step toward patient safety and ensures that this error will never happen again,” Dr. Carlson said. “Christopher’s memory inspires us to never give up telling his story and remaining vigilant for this cause.”

For more information about Just Bag It: The NCCN Campaign for Safe Vincristine Handling, or to report that a medical facility has adopted a vincristine policy, visit NCCN.org/justbagit.

###

>View Article<



07/21/2017
Empowering Patients to Talk about Sex
>View Article<



07/21/2017
Study Sheds Light on the ‘Other’ Breast Cancer Genes (CNN)
>View Article<



07/21/2017
Young Adult Survivors Struggle to Get Back to Normal (University of Michigan Comprehensive Cancer Center)
>View Article<



07/21/2017
No Dye: Cancer Patients’ Gray Hair Darkened on Immune Drugs (AP)
>View Article<



07/20/2017
Younger Age Predicts Node Positivity in T1 Melanoma (MedPage Today)
>View Article<



07/20/2017
More Patients Enrolled in Cancer Trials under ACA (Physician’s Weekly)
>View Article<



07/20/2017
Concurrent Chemotherapy, Proton Therapy Improves Survival in Patients with Advanced Lung Cancer (The University of Texas MD Anderson Cancer Center)
>View Article<



07/20/2017
Tobacco Companies are Looking towards Pharmaceuticalisation (Global Healthcare)
>View Article<



07/20/2017
Many Terminal Cancer Patients Remain in Denial (U.S. News and World Report)
>View Article<



07/20/2017
Immune-Cell Numbers Predict Response to Combination Immunotherapy in Melanoma (UCSF Helen Diller Family Comprehensive Cancer Center)
>View Article<



07/20/2017
Concurrent Chemotherapy, Proton Therapy Improves Survival in Patients with Advanced Lung Cancer (The University of Texas MD Anderson Cancer Center)
>View Article<



07/19/2017
Female Surgeons Making Inroads in Male-Dominated Operating Rooms (Hartford Courant)
>View Article<



07/19/2017
John McCain Has Brain Cancer, Senator’s Office Says (The New York Times)
>View Article<



07/17/2017
Epigenetic Assay Could Spare Patients from Additional Biopsies for Prostate Cancer (OncLive)
>View Article<



07/17/2017
Myeloma Trial Explores Optimal Induction, Maintenance Regimens (OncLive)
>View Article<



07/12/2017
Metastatic Cancer Cells Use Hedgehog to ‘Evilize’ Docile Neighbors (University of Colorado Cancer Center)
>View Article<



07/10/2017
NEJM case reports show promise of cancer immunotherapy to treat rare lymphoma
>View Article<